Could a repurposed drug put the brakes on Parkinson's?

NCT ID NCT02655315

Summary

This study tested whether a drug called deferiprone could slow the progression of Parkinson's disease. The drug works by removing excess iron from the brain, which researchers believe may contribute to the disease. The trial involved 372 adults with early-stage Parkinson's who were not yet on standard medications. Participants took either the drug or a placebo for nine months to see if it changed the course of their symptoms.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • AP-HP, Hôpital Pitié-Salpêtrière

    Paris, France

  • Acadamic central center, Amsterdam

    Amsterdam, Netherlands

  • CHU Pellegrin

    Bordeaux, France

  • CHU de Strasbourg, Hôpital de Hautepierre

    Strasbourg, France

  • CHU la TIMONE

    Marseille, France

  • Cambridge University Hospital

    Cambridge, United Kingdom

  • Centro Hospitalar Lisboa Norte

    Lisbon, Portugal

  • Centro Hospitalar do Alto Ave

    Guimarães, Portugal

  • Centro Hospitalar e universitario de Coimbra

    Coimbra, Portugal

  • Charles University

    Prague, Czechia

  • Christian-albrechts universität zu kiel

    Kiel, Germany

  • Chu Purpan

    Toulouse, France

  • Hospital Clinic Universitari de Barcelona

    Barcelona, Spain

  • Hospital de Bellvitge

    Barcelona, Spain

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

  • Hôpital Montpied

    Clermont-Ferrand, France

  • Hôpital Salengro, CHRU

    Lille, France

  • Hôpital Wertheimer

    Bron, France

  • Klinik und Poliklinik für Neurologie der Universitätsmedizin Rostock

    Rostock, Germany

  • Medizinische Universitat Innsbruck

    Innsbruck, Austria

  • Newcastle University

    Newcastle, United Kingdom

  • Radboud university medical center

    Nijmegen, Netherlands

  • University Hospital, Saarland University

    Homburg, Germany

  • University of Glasgow

    Glasgow, United Kingdom

  • Univerzita Karlova V Praze

    Prague, Czechia

Conditions

Explore the condition pages connected to this study.